APYX:NSD-Apyx Medical Corporation (USD)

COMMON STOCK | Medical Devices | NSD

Last Closing Price

USD 9.92

Change

+0.66 (+7.13)%

Market Cap

USD 0.32B

Volume

0.26M

Average Target Price

N/A
Average Analyst Rating

N/A

Fundamental Analysis

Verdict

About

Apyx Medical Corporation, a energy technology company, manufactures and sells medical devices in the cosmetic and surgical markets worldwide. It operates in two segments, Advanced Energy and Original Equipment Manufacturing (OEM). The company develops J-Plasma, a patented plasma-based surgical product for cutting, coagulation, and ablation of soft tissue. It markets and sells Helium Plasma Technology under the Renuvion brand name in the cosmetic surgery market and under the J-Plasma brand name in the hospital surgical market. The company's Renuvion cosmetic technology enables plastic surgeons, fascial plastic surgeons, and cosmetic physicians to provide controlled heat to the tissue; and the J-Plasma system allows surgeons to operate in eliminating unintended tissue trauma. It also designs, develops, manufactures, and sells electrosurgical and OEM generators and related accessories for medical device manufacturers. The company was formerly known as Bovie Medical Corporation and changed its name to Apyx Medical Corporation in January 2019. Apyx Medical Corporation was incorporated in 1982 and is based in Clearwater, Florida.

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2021-01-15 )

Largest Industry Peers for Medical Devices

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
ALGN Align Technology, Inc

+12.59 (+2.27%)

USD43.73B 25.24 103.27
PODD Insulet Corporation

-2.94 (-1.03%)

USD18.73B 645.77 144.08
ABMD Abiomed, Inc

+11.38 (+3.58%)

USD14.38B 69.96 57.33
LVGO Livongo Health, Inc

N/A

USD14.20B N/A N/A
BRKR Bruker Corporation

+0.31 (+0.52%)

USD8.99B 58.04 28.89
IART Integra LifeSciences Holdings ..

-0.09 (-0.13%)

USD5.71B 102.70 25.49
TNDM Tandem Diabetes Care, Inc

+0.37 (+0.41%)

USD5.68B N/A N/A
SWAV ShockWave Medical, Inc

-0.11 (-0.08%)

USD4.69B N/A N/A
SDC SmileDirectClub, Inc

-0.57 (-4.75%)

USD4.63B N/A N/A
WMGI Wright Medical Group N.V

N/A

USD3.90B N/A 50.67

ETFs Containing APYX

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Medical Devices)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 37.78% 94% A 94% A
Dividend Return N/A N/A N/A N/A N/A
Total Return 37.78% 94% A 94% A
Trailing 12 Months  
Capital Gain 22.17% 58% F 63% D
Dividend Return N/A N/A N/A N/A N/A
Total Return 22.17% 58% F 63% D
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain -9.32% 28% F 18% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -9.32% 28% F 16% F
Risk Return Profile  
Volatility (Standard Deviation) 14.23% 96% A 80% B-
Risk Adjusted Return -65.52% 19% F 9% F
Market Capitalization 0.32B 50% F 43% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Medical Devices)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 4.30 66% D 87% B+
Price/Book Ratio 4.22 59% F 37% F
Price / Cash Flow Ratio -17.18 68% D+ 83% B
EV/EBITDA N/A N/A N/A N/A N/A
Management Effectiveness  
Return on Equity -22.41% 61% D- 33% F
Return on Invested Capital -26.04% 57% F 27% F
Return on Assets -18.47% 38% F 20% F
Debt to Equity Ratio N/A N/A N/A N/A N/A
Technical Ratios  
Short Ratio 8.89 14% F 10% F
Short Percent 1.59% 87% B+ 69% D+
Beta 0.72 69% D+ 78% C+
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

What to not like:
Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.

Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector